Prostatype Genomics / Investor relations / Offering Documents

Offering Documents

Current offer
Previous Offers
Translated documents

Important information

Due to legal restrictions, the information on this website is only intended for certain recipients. Recipients of this offer in jurisdictions where this offer has been published or distributed should inform themselves of and comply with such restrictions. This offer does not constitute an offer to, or an invitation to, acquire or subscribe for any securities of the Company in any jurisdiction, either from Prostatype Genomics or any other party, where such an offer would be unlawful. No action has been taken, and no action will be taken, to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics will only be made through the information memorandum that Prostatype Genomics intends to publish before the subscription period commences.

The information on this website may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, according to the United States Securities Act of 1933, as amended (“Securities Act”), or the securities legislation of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities legislation of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of the Article 19(5), as amended, of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“the Order”) or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as “Relevant Persons”). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

Rights issue 2026

On 29 June 2026, Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) announced that the Board of Directors had resolved to carry out an issue of units – shares and two series of warrants – of initially up to approximately SEK 47.4 million before transaction costs with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Rights Issue is covered by pre-subscription commitments, bottom- and top-town underwriting undertakings totalling approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. The purpose of the Rights Issue is to finance the continued Medicare reimbursement approval process and commercialization activities in the United States and Europe.

Informationsmemorandum (SWE)
I nformation memorandum (ENG)

Teaser (SWE)
Teaser (ENG)

THE OFFER IN BRIEF

Subscription period: 9 July – 23 July 2026.

Please note that your bank or broker for administrative reasons may adopt a shorter exercise period than to 23 July 2026. For questions about your specific deadline, please contact your bank/broker.

Subscription price: SEK 0.80 per unit, corresponding to SEK 0.10 per share. Warrants of series TO6 and TO7 are issued free of charge.
Unit rights: The last day of trading in the Company’s shares with the right to receive unit rights is 3 July 2026. One (1) unit right entitles the holder to subscribe for one (1) unit. One (1) unit consists of eight (8) shares, two (2) warrants of series TO6 and four (4) warrants of series TO7.
Issue volume: initially up to approximately SEK 47.4 million before transaction costs. Provided that all warrants of series TO6 and TO7 are issued and exercised at their respective maximum exercise prices, the Company may receive additional proceeds of approximately SEK 59.2 million before transaction costs.
Pre-subscription and guarantee commitments: The Rights Issue is contractually secured to a total of approximately 91.3 percent (corresponding to approximately SEK 43.2 million) through pre-subscription commitments and bottom- and top-down guarantee commitments. Of the subscription commitments, which amount to approximately SEK 9.2 million in total, approximately SEK 8.0 million is intended to be settled through set-off against outstanding shareholder loans, accrued interest thereon and other outstanding liabilities.
Dilution: Shareholders who choose not to participate in the Rights Issue will, assuming that the Rights Issue is fully subscribed, have their ownership diluted by approximately 88.9 percent. Such shareholders will, however, have the opportunity to compensate themselves financially for this dilution by selling their unit rights.
Warrants of series TO6: Each (1) TO6 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise price for warrants of series TO6 will be SEK 0.10 per share, corresponding to both the subscription price per share in the Rights Issue and the share’s quota value. The TO6 warrants may be exercised for subscription of new shares in Prostatype Genomics during the period from 1 September 2026 up to and including 15 September 2026. The TO6 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the TO6 warrants is expected to be 11 September 2026.

Upon full exercise of all TO6 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 11.8 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 0.6 million.
Warrants of series TO7: Each (1) TO7 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise period for the TO7 warrants is event-driven and is contingent upon the Company obtaining Medicare reimbursement approval. The exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company’s share on Nasdaq First North Growth Market during a measurement period comprising the ten (10) trading days preceding the Company’s announcement of Medicare reimbursement approval. However, the exercise price shall not be lower than SEK 0.10 per share and not higher than SEK 0.20 per share. As the primary alternative, an exercise period of ten (10) trading days shall commence three (3) trading days after the Company has announced, by way of a press release, that its Medicare application has been approved, but no earlier than 1 September 2026 and no later than 7 December 2026.

Alternatively, if approval of the Company’s Medicare application has not been announced and no exercise period has been determined within the timeframe set out above, the exercise period shall commence on 7 December 2026 and remain open for ten (10) trading days, up to and including 21 December 2026. In such case, the exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company’s share during the ten (10) trading days ending two trading days prior to the commencement of the exercise period on 7 December 2026.

Accordingly, the ten (10) trading day exercise period for the TO7 warrants may commence no earlier than 1 September 2026 and no later than 7 December 2026 and are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the TO7 warrants is expected to be no later than 17 December 2026.

Upon full exercise of all TO7 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 47.4 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 2.2 million.
Oversubscription: In the event that the Rights Issue is oversubscribed and persons or entities that have entered into subscription commitments without preferential rights are not allocated units, in whole or in part, to an extent sufficient to fulfil their commitments, the Company intends to resolve on a separate directed issue of units (a so-called over-allotment issue). The terms and conditions of any such directed issue of units will correspond to those of the Rights Issue.

Documents related to the offer

The Board’s resolution on rights issue
T erms for Warrants of series TO6
Terms for Warrants of series TO7
The Board’s report on events of material significance
The Auditor’s statement on events of material significance (Swedish)
The Board’s report on set-off of claims
The Auditor’s statement on set-off of claims (Swedish)

Advisors

Navia Corporate Finance AB and Birchtree Advisory AB are financial advisors and Bookrunners in connection with the Rights Issue. Advokatfirman Lindahl is the legal advisor. Vator Securities AB is the issuing agent.

For more information about the Rights Issue, please contact:

Navia Corporate Finance AB
E-mail: info@naviacf.se

Website: www.naviacorporatefinance.com
or
Birchtree Advisory AB
E-mail: jonas.bjorkman@birchtreeadvisory.se
Website: www.birchtreeadvisory.se